Skip to main content

All Articles

The Imperative to Discuss Cost of Care with Patients with Cancer

By Michael Kolodziej, MD, FACP

April 2015, Vol 5, No 3

Cost of Regorafenib versus Benefit Analyzed in Patients with Metastatic Colorectal Cancer

April 2015, Vol 5, No 3

Bringing the Oncology Care Model into Focus Patient and Provider Access

April 2015, Vol 5, No 3

Confirming Diagnoses and Identifying Biomarkers Linked to Targeted Treatments with the bioT3 Approach

April 2015, Vol 5, No 3

Why You Need Disability Insurance: A Doctor’s Story

By Stuart E. Lowenkron, MD

Financial Management, Practice Management

April 2015, Vol 5, No 3

Clinical Trials Under Way for Patients with Renal-Cell Carcinoma

Clinical Trials Tracker

April 2015, Vol 5, No 3

Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer

By Loretta Fala

April 2015, Vol 5, No 3

FDA-Approved Medications Used for the Treatment of Colorectal Cancer

April 2015, Vol 5, No 3

Innovations in Oncology Management, Vol. 2 No. 4

Engaging with Local Payers: The Oncology Practice Perspective

Innovations in Oncology Management, Part 4

Although oncology practices and providers can agree on the ultimate goal of efficient, patient-centered treatment, they may not, however, agree on the details of how oncology management should evolve. Read More ›

Page 268 of 299